[go: up one dir, main page]

WO2003001877A3 - Methods for the diagnosis and treatment of cardiac tissue rejection - Google Patents

Methods for the diagnosis and treatment of cardiac tissue rejection

Info

Publication number
WO2003001877A3
WO2003001877A3 PCT/US2002/019971 US0219971W WO03001877A3 WO 2003001877 A3 WO2003001877 A3 WO 2003001877A3 US 0219971 W US0219971 W US 0219971W WO 03001877 A3 WO03001877 A3 WO 03001877A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosis
treatment
cardiac tissue
tissue rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019971
Other languages
French (fr)
Other versions
WO2003001877A2 (en
Inventor
Daniel P Bednarik
Kenneth B Margulies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Priority to AU2002322301A priority Critical patent/AU2002322301A1/en
Publication of WO2003001877A2 publication Critical patent/WO2003001877A2/en
Publication of WO2003001877A3 publication Critical patent/WO2003001877A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods are provided for diagnosing and detecting cardiac rejection in transplant patients. Elevated levels of BlyS are found to be closely associated with cardiac rejection in transplant patients. Methods and compositions for blocking the expression and/or activity of BlyS are described that inhibit or prevent tissue rejection in cardiac transplant patients.
PCT/US2002/019971 2001-06-26 2002-06-26 Methods for the diagnosis and treatment of cardiac tissue rejection Ceased WO2003001877A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002322301A AU2002322301A1 (en) 2001-06-26 2002-06-26 Methods for the diagnosis and treatment of cardiac tissue rejection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30061701P 2001-06-26 2001-06-26
US60/300,617 2001-06-26

Publications (2)

Publication Number Publication Date
WO2003001877A2 WO2003001877A2 (en) 2003-01-09
WO2003001877A3 true WO2003001877A3 (en) 2003-09-12

Family

ID=23159860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019971 Ceased WO2003001877A2 (en) 2001-06-26 2002-06-26 Methods for the diagnosis and treatment of cardiac tissue rejection

Country Status (2)

Country Link
AU (1) AU2002322301A1 (en)
WO (1) WO2003001877A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6897164B2 (en) 2002-02-14 2005-05-24 3M Innovative Properties Company Aperture masks for circuit fabrication
WO2008109356A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnfsf13b gene expression and uses thereof
SI2139517T1 (en) 2007-03-27 2013-09-30 Zymogenetics, Inc. Combination of blys inhibition and mycophenolate mofetil for treatment of autoimmune disease
US9176147B2 (en) * 2009-10-29 2015-11-03 Wisconsin Alumni Research Foundation Detection of B-cell activating factor as a biomarker for antibody mediated rejection in transplant recipients
CN102298054A (en) * 2011-05-27 2011-12-28 湘潭陆峰生物科技有限公司 Swine anti-human T cell enzyme linked immunosorbent assay (ELISA) kit and detection method thereof
US20210347873A1 (en) * 2016-07-06 2021-11-11 Shanghai Pharmaexplorer Co., Ltd. Blys antibody, preparation method therefor and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989912A (en) * 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
WO2001075164A2 (en) * 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989912A (en) * 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
WO2001075164A2 (en) * 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOORE ET AL.: "BLys: member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, vol. 28, July 1999 (1999-07-01), pages 260 - 263, XP002142252 *
SCHNEIDER ET AL.: "BAFF a novel ligand of the tumor necrosis factor family, stimulates B cell growth", J. EXP. MED., vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409 *
ZHANG ET AL.: "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus", JOURNAL OF IMMUNOLOGY, vol. 166, January 2001 (2001-01-01), pages 6 - 10, XP002960695 *

Also Published As

Publication number Publication date
AU2002322301A1 (en) 2003-03-03
WO2003001877A2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
WO2004003164A3 (en) Methods of organ regeneration
SI1546088T1 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
BR0315645A (en) Actrib fusion polypeptides and their uses
BR0016154A (en) Depsipeptide and its counterparts for use as immunosuppressants
PT1682126E (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2007100622A3 (en) Variably crosslinked tissue
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
EP2548880A3 (en) Compositions for increasing telomerase activity
ATE490778T1 (en) USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
DE60215866D1 (en) MEDICAMENT CONTAINING CYANIDINE-3-GLYCOSIDE AS AN ACTIVE AGENT AGAINST FAT SUPPORT AND DIABETES
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
WO2007070301A3 (en) Vascular graft sterilization and decellularization
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2006047841A3 (en) Engineering with homing factors
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
ATE442854T1 (en) USE OF 5'-METHYLTHIOADENOSINE FOR THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION
ATE79265T1 (en) AGENT FOR THE TREATMENT OF MYCOTIC, MICROBIC AND OTHER TISSUE-DAMAGING AND PATHOLOGICAL MANIFESTATIONS AND TISSUE DEFORMATIONS.
EP1664775A4 (en) Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP